Heavy Use of Botanical Sources in Biopharmaceutical Plants

Biopharmaceutical plants accounts for the total production of medicines. But the major challenge faced by them is that they are using resources belonging to animal origin. To meet the growing demand of market, therapeutic proteins obtained from animal tissues are not sufficient. Substitutes for this are to be searched for the further expansion of Pharmaceutical engineering.

The solution for this challenge is found out by modern biotechnology. They have created genetically engineered plants which has the ability to substitute animal resources. These genetically engineered plants have the capability of producing affordable medicines which can meet the growing demand. They can produce recombinant proteins which includes cytokines, blood product alternatives, mammalian antibodies, vaccines and several curative agents. Biotechnology has contributed a lot to Pharmaceutical engineering.

Proper gene expression system and host selection is mandatory for biopharmaceutical plants. The drug development procedure starts from incorporation of DNA of intended molecule into the specified host plant. This process replicates the target molecule during its growth. During the refinement and revival process, antibodies are produced in the host plant. This procedure has proved its proficiency and is eye-catching for pharmaceutical industries. Biopharmaceuticals is able to meet the growing demand because of the efficient methods like storing, processing and existing crop harvesting.

Use of genetically engineered plant for the manufacture of drugs is a recent development of Biotechnology but it has the potential to take the world of Pharmaceutical engineering to new heights. It has all the qualities indispensable for large scale drug development like less preliminary investment, simple recuperation, safety, proper purification etc. It has increased the production to many folds. Yet Biopharmaceutical plants cannot completely depend upon genetically engineered plants for drug development as this technology is very new and not completely expanded.

As compared to other pharmaceutical units, biopharmaceuticals have a tremendous growth. Now, biopharmaceuticals are using the concept of genetically altered plants. In the midst of so many advantages, there are several disadvantages too if these are not used properly. Several strategies have to be followed for its use or else it can badly affect the expansion of this unit.

For more information on Biopharmaceutical plants and the benefits of Biopharmaceutical plants please visit the mentioned website

Article Source: http://EzineArticles.com/?expert=Anjali_Goswami
http://EzineArticles.com/?Heavy-Use-of-Botanical-Sources-in-Biopharmaceutical-Plants&id=4454641

Pros and Cons of Biotechnology Using Mammalian Expression Systems

In biotechnology, protein mammalian expressions refer to the method of transfecting genes into bovines to create fully folded proteins. End clients can either culture their own monoclonal antibodies through various cell types (hybridomas, human cell lines, CHO, etc.), or they could partner with contract manufacturing organizations that can deliver loads of recombinant proteins from a good range of sources.

Pros of using bovine protein expressions

The presence of post gene modifications is seen to produce the highest functionality. The resulting recombinant proteins can further be modified through post-transnational procedures on the bovine cells. Cycotoxic Antibody Conjugates through mammalian expression are also found to be most compatible to humans. In the same vein, they also have very low immunogenicity as well as high immunity to human pathogens. In short, they are very safe for human use. All these factors mean that the path toward getting permission from regulatory bodies is much easier when you go through the mammalian expression route.

The cons of mammalian expression

Unfortunately, no method is perfect. This is particularly true with recombinant proteins where integration with various cell types can produce various results along with their ensuing consequences. In the case of bovine expression, it's quite difficult to initiate transfection of gene of interest into the bovine cell. Also, extracting a single clone is a very laborious process when you compare it to the other expression methods such as bacteria, insect cell, yeast, eukaryotic using plants, and cell-free systems. These are just some of the contributing factors why the production rate using mammalian expression is still low. And this is the reason why protein culture and producing monoclonal antibodies using bovine expression is quite costly. To bypass the very time-consuming process, biotech companies can partner with contract manufacturing organizations (CMOs) that can deliver their requirements.

Choosing CMOs

Admittedly, the sheer number of CMOs out there makes it difficult to choose the ideal partner. A good tip is to look at biologic manufacturing companies that earn the respect of their peers and experts. The CMO must be able to deliver solutions even with the most complicated problems presented to it, covering a whole gamut of services including Biobetters, biosimilars, cell line development and cell banking, transgenics, GMP manufacturing, bioconjugation, aseptic fill and finish, and consulting services. A good way to start is at the top, meaning you choose from the winners of the annual CMO Leadership Awards by Life Science Leaders magazine.

Good Win Bio is an experienced Content writer and publisher for Business Development. Visit at http://www.goodwinbio.com/ to know more about Mammalian Expression Systems and Biobetters.

Article Source: http://EzineArticles.com/?expert=Juliana_Clark
http://EzineArticles.com/?Pros-and-Cons-of-Biotechnology-Using-Mammalian-Expression-Systems&id=7502018